STAT5A and breast cancer: Persistent prolactin receptor signalling has been shown in STAT1-deficient mammary epithelial cells, and this results in the activation of JAK2, STAT3 and STAT5A/5B, and the subsequent development of oestrogen receptor-α-positive mammary tumours [80,81].